



Bu proje Avrupa Birliđi ve Türkiye Cumhuriyeti tarafından finanse edilmektedir
This project is co-funded by the European Union and the Republic of Türkiye



Türkiye in Horizon 2020 Phase II

Charlotte Gudewicz

French national cancer institute (INCa)

TRANSCAN-3 JTC2023 International Info Day and Networking Event, 16 May 2023



TRANSCAN

Sustained collaboration of national
and regional programmes in cancer research

Joint Transnational Call for Proposals 2023 (JTC 2023)

Translational research on cancer epigenetics

JTC 2023 - 19 COUNTRIES / 24 FUNDING ORGANISATIONS

- **Austria:** Austrian Science Fund (FWF)
- **Belgium** French speaking community: Fund for Scientific Research - FNRS (F.R.S.-FNRS)
- **Canada:** Canadian Institutes of Health Research (CIHR)
- **Estonia:** Estonian Research Council (ETAg)
- **France:** ARC French Foundation for Cancer Research (ARC Foundation),
French National Cancer Institute (INCa)
- **Germany:** Federal Ministry of Education and Research (BMBF)
- **Hungary:** National Research, Development and Innovation Office (NKFIH)
- **Ireland:** Health Research Board (HRB)
- **Italy:** Ministry of Health (IT-MOH),
Tuscany Region (TuscReg), Tuscany,
Fondazione Regionale per la Ricerca Biomedica (FRRB),
Lombardy
- **Israel:** The Chief Scientist Office of the Ministry of Health (CSO-MOH)
- **Latvia:** Latvian Council of Science (LCS)
- **Luxembourg:** National Research Fund (FNR)
- **Norway:** Norwegian Cancer Society (NCS),
Research Council of Norway (RCN)
- **Poland:** National Centre for Research and Development (NCBR)
- **Romania:** Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)
- **Slovakia:** Slovak Academy of Sciences (SAS)
- **Spain:** National Institute of Health Carlos III (ISCIII),
The Scientific Foundation of the Spanish Association Against Cancer (FCAECC)
- **Taiwan:** National Science and Technology Council (NSTC)
- **Türkiye:** The Scientific and Technological Research Council of Türkiye (TÜBİTAK)

JTC 2023 - AIMS of the CALL

Aim 1) The role of epigenetics in cancer initiation and progression. These studies may aim to validate novel epigenetics-based biomarkers to improve detection, diagnosis, prognosis of cancers or response to therapies.

- To understand cancer initiation and progression by characterisation of the epigenetic landscape.
- To define epigenetic features of cells in the tumour microenvironment that may promote tumour progression (e.g., immune cells, vascular cells, microbiota).
- To study the role of epigenetic modifications as predictors of cell persistence or treatment resistance.
- To validate epigenetic markers useful to improve early detection and diagnosis by exploring the correlation between epigenetics and clinical cancer manifestation.

JTC 2023 - AIMS of the CALL

Aim 2) Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.

- To validate novel therapeutic targets (novel targets should be evaluated in translational studies with regard to their impact on treatment efficacy, safety and patient reported outcomes).
- To study the potential use of epigenetic modulators to overcome resistance to anti-cancer therapies.
- To develop novel epidrugs/therapeutic approaches, through phase I and II clinical trials (investigating combinations of available treatments, new therapeutics, new administration schemes, etc.) to improve safety and efficacy of treatments (objective responses; patient reported outcomes regarding morbidity and quality of life; ...).
- To develop novel theranostic approaches involving epigenetics of cancer. Approaches combining diagnostic (imaging technics) and targeted treatment to detect cancer cells and assess treatment efficacy (radionuclide, radiopharmaceuticals, nanoparticles, nanomaterial, ...).

JTC 2023 - RESEARCH CONSORTIUM

- Each research consortium must involve a **minimum of three (3) and a maximum of six (6) partners, eligible for funding**, from different countries whose funders participate in the call.
- The partners must be **from at least three (3) different countries participating in the call**.
- A consortium must **not involve more than two (2) research groups from the same country**.
- A wide inclusion of research teams from **all the countries/regions** participating in the call is encouraged, therefore **the maximum number of partners can be increased up to seven (7) if they include one partner from Hungary, Latvia, Slovakia or Türkiye**.
- One partner not eligible for funding (e.g. from non-funding countries or not fundable according to the regional/national regulations) can participate in a proposal with its own funding.
- Each consortium must involve at least one basic or pre-clinical research team and one clinical team.

JTC 2023 - A TWO-STEP CALL

Submission by the coordinator of the consortium : <https://ptoutline.eu/app/transcan2023>



PT-Outline

Site notice Privacy Support

TRANSCAN2023

Translational research on cancer epigenetics

Login Sign up Recover password

Email:

Password

Login

[Forgot your password?](#)

TRANSCAN-3
ERA-NET: Sustained collaboration of national and regional programmes in cancer research
Joint Transnational Call for Proposals 2023 (JTC 2023)

" Translational research on cancer epigenetics "

Pre-proposal Application Form

All fields must be filled in using Arial font, size 11, single-spaced.
Applications should be submitted as a PDF file, formatted in DIN-A4.

Please note that proposals either incomplete, using a different format or exceeding length limitations of any sections will be rejected without further review.

1a. Project title (maximum 150 characters, including spaces):

1b. Project acronym (maximum 10 characters):

2. Project duration (months):

3. Project coordinator (research partner 1 in the consortium):

Name	
Country	
Position	
Institution/Department	
Address	
Phone + Fax	
E-mail address	
Type of entity (tick as appropriate)	<input type="checkbox"/> Academia (universities or other higher education or research institutions) <input type="checkbox"/> Clinical or Public Health Sector (hospitals/public health and/or other health care settings and health organisations) <input type="checkbox"/> For-profit Private Organisation <input type="checkbox"/> Non-profit Private Organisation

Specific eligibility check for teams from Israel, Italy, Spain and Türkiye

JTC 2023 - FIRST STEP: PRE-PROPOSALS

ELIGIBILITY CHECK

Joint Call Secretariat check: Eligibility criteria outlined on the Call text (number of participating countries and groups, inclusion of all necessary information, adherence to the application forms, document length)

National/regional eligibility check: Adherence to the funding organisation rules

Non-compliance with the eligibility rules will lead to the rejection of the entire proposal without further review

EVALUATION OF ELIGIBLE PRE-PROPOSALS

Each pre-proposal will be allocated to two (2) SEC members.

Evaluation criteria: **1. Excellence (scientific quality, relevance)**

2. Impact

3. Quality and efficiency of the implementation (methodology, technologies, statistical aspects, consortium, management)

JTC 2023 – WIDENING PROCESS

To maximise the involvement of underrepresented countries → Opportunity to add one partner from a country that will likely not spend his earmarked budget (the list will be indicated after pre-proposal evaluation).

- Only one team from an underrepresented country may join a consortium.
- Funding of the new partner must be provided by the respective funding organisation.
- The work plan of proposals which have already been evaluated must not be changed (i.e. new work packages or tasks should be added and existing work packages must not be modified).
- The maximum number of participating partners can be increased to seven.

Coordinators of successful pre-proposals will be informed about the possibility to benefit from inclusion of one team from an underrepresented country in their consortium.

JTC 2023 - SECOND STEP: FULL-PROPOSALS

ELIGIBILITY CHECK

No substantial change in the full proposal is allowed unless those exceptionally agreed with the Joint Call Secretariat.

EVALUATION OF ELIGIBLE FULL-PROPOSALS

Each pre-proposal will be allocated to three (3) SEC members.

If necessary, additional experts chosen for their knowledge in specific fields covered by the proposals may also be invited to join the SEC.

Evaluation criteria: **1. Excellence**
2. Impact
3. Quality and efficiency of the implementation

JTC 2023 - FUNDING

The selection of projects to be funded will be made based on the ranking list established by the SEC and on the commitment of available funds.

- The TRANSCAN partners will use the “virtual common pot” model to fund research projects.
 - Each national/regional funding organisation will fund research groups from its own country/region in accordance with applicable national/regional specific regulations.
 - Each research partner within a consortium (including the project coordinator) will get a funding contract/letter of grant from their respective national/regional funding organisations.
- Eligibility criteria and administrative requirements of each funding may vary from one country/region to another.

→ So please check ANNEX 3 of the Call Text and the national/regional regulations of your organisation on the Guidelines for Applicants.

JTC 2023 - Timeline of the call

9 May 2023	Publication of the call
29 May 2023 at 16:00 (CEST)	Opening of the on-line submission system for pre-proposals
21 July 2023 at 12:00 (CEST)	Deadline for pre-proposal submission
27 October 2023	Communication of the results of the pre-proposal assessment and invitation for full-proposal stage
13 November 2023	Opening of the submission system for full proposals
15 December 2023 at 12:00 (CET)	Deadline for full-proposal submission
Expected for May 2024	Communication of the funding decisions to the applicants
September 2024	Expected project start (also subject to regional/national procedures)

For any additional information or questions, please
contact us

Joint Call Secretariat (JCS) :
French national cancer institute
Charlotte Gudewicz
transcan-jtc2023@institutcancer.fr



TRANSSCAN

Sustained collaboration of national
and regional programmes in cancer research